Cyclo Therapeutics Inc Revenue Growth Rates (CYTH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cyclo Therapeutics Inc   (NASDAQ: CYTH)
 

CYTH's Revenue Growth by Quarter and Year

Cyclo Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYTH Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 0.23
2nd Quarter June 0.12
1st Quarter March 0.20
FY 0.55

CYTHs Annual Revenue
Cyclo Therapeutics Inc 's Revenue in the fiscal year 2024 $ 1.08 millions
Cyclo Therapeutics Inc 's Revenue in the fiscal year 2023 $ 1.08 millions
Cyclo Therapeutics Inc 's Revenue in the fiscal year 2022 $ 1.38 millions
Cyclo Therapeutics Inc 's Revenue in the fiscal year 2021 $ 1.59 millions
Cyclo Therapeutics Inc 's Revenue in the fiscal year 2020 $ 0.90 millions




CYTH Revenue third quarter 2024 Y/Y Growth Comment
Cyclo Therapeutics Inc reported drop in Revenue in the third quarter 2024 by -53.25% to $ 0.23 millions, from the same quarter in 2023.
The fall in the third quarter 2024 Cyclo Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 21.46%.

Looking into third quarter 2024 results within Biotechnology & Pharmaceuticals industry 59 other companies have achieved higher Revenue growth. While Cyclo Therapeutics Inc ' s Revenue meltdown of -53.25% ranks overall at the positon no. 3826 in the third quarter 2024.


CYTH Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 63.16 % -67.8 % 293.33 %
3rd Quarter September -53.25 % 11.11 % 12.5 % 81.82 %
2nd Quarter June 0 % -77.78 % 125 % 14.29 %
1st Quarter March 33.33 % -21.05 % -47.22 % 9.09 %
FY   - -21.17 % -13.84 % -

Financial Statements
Cyclo Therapeutics Inc 's third quarter 2024 Revenue $ 0.23 millions CYTH's Income Statement
Cyclo Therapeutics Inc 's third quarter 2023 Revenue $ 0.50 millions Quarterly CYTH's Income Statement


CYTH Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - -38 % -57.78 % 47.5 %
3rd Quarter September 94.81 % 316.67 % -16.67 % 66.67 %
2nd Quarter June -40 % -20 % 184.21 % -33.33 %
1st Quarter March -35.48 % -21.05 % -67.8 % 140 %
FY (Year on Year)   - -21.17 % -13.84 % -


Back to CYTH Growth rate Comparisons >> Back to CYTH Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #60
Healthcare Sector #544
Overall #3826

Revenue Y/Y Growth Statistics
High Average Low
382.83 % 21.46 % -78.39 %
(Sep. 30, 2015)   (Jun 30 2023)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #60
Healthcare Sector #544
Overall #3826
Revenue Y/Y Growth Statistics
High Average Low
382.83 % 21.46 % -78.39 %
(Sep. 30, 2015)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Cyclo Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
323.06 % 22.36 % -72.85 %
(Sep 30 2023)  


CYTH's III. Quarter Q/Q Revenue Comment
Cyclo Therapeutics Inc achieved in the III. Quarter 2024 above company average sequential Revenue jump of 94.81%, to $ 0.23 millions, from $0.12 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Cyclo Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 198.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #62
Overall #198
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #62
Overall #198
Revenue Q/Q Growth Statistics
High Average Low
323.06 % 22.36 % -72.85 %
(Sep 30 2023)  


CYTH's III. Quarter Q/Q Revenue Comment
Cyclo Therapeutics Inc achieved in the III. Quarter 2024 above company average sequential Revenue jump of 94.81%, to $ 0.23 millions, from $0.12 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Cyclo Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 198.


Cyclo Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 0.87 $ 1.13 $ 1.13 $ 1.08 $ 0.95
Y / Y Revenue Growth (TTM) -8.52 % 24.65 % -15.51 % -21.76 % -46.35 %
Year on Year Revenue Growth Overall Ranking # 2859 # 2452 # 1842 # 2074 # 294
Seqeuential Revenue Change (TTM) -23.11 % 0.53 % 4.65 % 13.09 % 4.77 %
Seq. Revenue Growth (TTM) Overall Ranking # 1274 # 2374 # 1897 # 2277 # 1631


Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2024 Cyclo Therapeutics Inc reported a decrease in Revenue by -8.52% year on year, to $1 millions, compare to the 24.65% growth at Jun 30 2024.

In the Healthcare sector 432 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2452 to 2859.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 433
Overall # 2859

Revenue TTM Y/Y Growth Statistics
High Average Low
621.96 %
 21.83 %
-47.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 249
S&P 500 # 1274
Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2024 Cyclo Therapeutics Inc reported a decrease in Revenue by -8.52% year on year, to $1 millions, compare to the 24.65% growth at Jun 30 2024.

In the Healthcare sector 432 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2452 to 2859.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 433
Overall # 2859

Revenue TTM Y/Y Growth Statistics
High Average Low
621.96 %
21.83 %
-47.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 249
S&P 500 # 1274




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CYTH's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
West Pharmaceutical Services Inc -0.08%$ -0.080 millions
Nektar Therapeutics-0.08%$ -0.083 millions
Apyx Medical Corp-0.22%$ -0.219 millions
Avantor Inc -0.34%$ -0.337 millions
Avanos Medical Inc -0.35%$ -0.352 millions
Integra Lifesciences Holdings Corp-0.41%$ -0.415 millions
Nuwellis Inc -0.59%$ -0.588 millions
Alkermes Plc -0.73%$ -0.734 millions
Prestige Consumer Healthcare Inc -0.92%$ -0.922 millions
Psychemedics Corporation-1.02%$ -1.021 millions
Petros Pharmaceuticals inc -1.34%$ -1.342 millions
10x Genomics Inc -1.39%$ -1.391 millions
Abcellera Biologics Inc -1.39%$ -1.394 millions
Nephros Inc -1.41%$ -1.409 millions
Charles River Laboratories International inc -1.64%$ -1.642 millions
Inspiremd Inc -1.67%$ -1.669 millions
Cv Sciences Inc -1.69%$ -1.691 millions
Elutia Inc -1.71%$ -1.712 millions
Enhabit Inc -1.82%$ -1.820 millions
Accuray Incorporated-1.96%$ -1.956 millions
Zimvie Inc -1.98%$ -1.984 millions
Reflect Scientific Inc-2.25%$ -2.254 millions
Upstream Bio Inc -2.25%$ -2.254 millions
Maravai Lifesciences Holdings Inc -2.49%$ -2.490 millions
Biogen Inc -2.55%$ -2.549 millions
Fresenius Medical Care Ag-2.66%$ -2.658 millions
Opko Health Inc -2.78%$ -2.779 millions
Precision Optics Corporation Inc -2.87%$ -2.874 millions
Msa Safety Inc-2.98%$ -2.985 millions
Teladoc Health Inc -2.99%$ -2.988 millions


About Cyclo Therapeutics Inc Revenue Growth Rates (CYTH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cyclo Therapeutics Inc (CIK 922247).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-24-035006
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cyclo Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.